Skip to main content

Genitourinary cancers

News and opinion

14-03-2019 | Aspirin | News

Aspirin does not improve prostate cancer-specific survival, but may reduce lung cancer incidence

A Danish study has found no protective effect of low-dose aspirin taken after diagnosis on prostate cancer-specific mortality, while South Korean research has identified a link between long-term use of the nonsteroidal anti-inflammatory drug and a reduced risk for incident lung cancer.

13-03-2019 | Castration-resistant prostate cancer | News

Phase III data show no support for PROSTVAC in mCRPC

A phase III trial investigating the efficacy of PROSTVAC, a viral vector–based immunotherapy, in the treatment of metastatic castration-resistant prostate cancer was stopped early due to a lack of positive results, say researchers.

12-03-2019 | Prostate cancer | News

Intense neoadjuvant ADT explored in locally advanced prostate cancer

Intense androgen deprivation therapy before radical prostatectomy benefits some patients with locally advanced prostate cancer, report researchers who found that results may be better with a four-drug than a two-drug regimen.

08-03-2019 | Prostate cancer | News

Hypofractionated RT noninferior to conventional for QoL in low-risk prostate cancer

Hypofractionated radiotherapy is similar to conventional radiotherapy when it comes to health-related quality of life in men with low-risk prostate cancer, according to the RTOG 0415 phase III randomized controlled trial.

07-03-2019 | Testicular cancer | News

Adjuvant testicular cancer treatment may not adversely affect sperm count, concentration

One course of adjuvant chemotherapy or radiotherapy does not appear to have a negative effect on sperm count or concentration over the long term in men with clinical stage I testicular cancer, suggests research.

06-03-2019 | Castration-resistant prostate cancer | News

Enzalutamide preserves QoL in men with nonmetastatic CRPC

Men with nonmetastatic, castration-resistant prostate cancer receiving enzalutamide maintain their low baseline pain levels and prostate cancer symptom burden and report high health-related quality of life, indicates a patient-reported outcomes analysis of the phase III PROSPER study.

05-03-2019 | Renal cell carcinoma | News

Cabozantinib efficacy extends to non-clear-cell RCC

Almost three-quarters of patients with non-clear-cell renal cell carcinoma may benefit from treatment with the tyrosine kinase receptor inhibitor cabozantinib, suggesting its efficacy is not limited to clear-cell disease, say researchers.

01-03-2019 | Immunotherapy | News

Sex disparity identified for hyperprogressive disease after immunotherapy

Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.

25-02-2019 | Castration-resistant prostate cancer | News

Combined radium-223, abiraterone acetate not endorsed for CRPC

Combining radium-223 with abiraterone acetate plus prednisone or prednisolone is not recommended for patients with castration-resistant prostate cancer and bone metastases, ERA 223 researchers report.

22-02-2019 | Castration-resistant prostate cancer | News

CheckMate 650: Nivolumab–ipilimumab potential for mCRPC demonstrated

The combination of nivolumab and ipilimumab has antitumor activity in men with metastatic castration-resistant prostate cancer, suggest CheckMate 650 data.

21-02-2019 | Renal cell carcinoma | News

Immunotherapy-based regimens show promise in non-clear-cell RCC

Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.

20-02-2019 | Renal cell carcinoma | News

Tivozanib improves refractory advanced RCC outcomes

The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.

19-02-2019 | Castration-sensitive prostate cancer | News

ARCHES shows enzalutamide benefit for mCSPC

Supplementing androgen deprivation therapy with enzalutamide delays radiologic progression in men with metastatic castration-sensitive prostate cancer, indicate phase III trial findings presented at the 2019 ASCO Genitourinary Cancers Symposium.

19-02-2019 | Renal cell carcinoma | News

Pembrolizumab–axitinib boosts untreated advanced RCC survival

Overall survival is significantly improved with the first-line combination of pembrolizumab and axitinib relative to sunitinib in patients with advanced renal cell carcinoma, shows the KEYNOTE-426 trial.

18-02-2019 | Castration-resistant prostate cancer | News

Darolutamide reduces CRPC metastasis risk

Addition of the androgen receptor antagonist darolutamide to androgen deprivation therapy improves metastasis-free survival in patients with castration-resistant prostate cancer, indicate ARAMIS trial results.

15-02-2019 | Castration-resistant prostate cancer | News

Further support for [177Lu]-PSMA-617 in men with mCRPC

Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.

15-02-2019 | Castration-resistant prostate cancer | News

Real-world data confirm better mCRPC OS with hormonal therapy in Black versus White men

An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.

14-02-2019 | Prostate cancer | News

Long-term data support SBRT for low-, intermediate-risk prostate cancer

Stereotactic body radiotherapy has a favorable long-term disease control and safety profile in the setting of low- or intermediate-risk prostate cancer, say US researchers who analyzed individual patient data from over 2000 prospectively treated men.

12-02-2019 | Prostate cancer | News

Conservative management of low-risk prostate cancer increasing in USA

US patients with low-risk localized prostate cancer are increasingly being managed with active surveillance or watchful waiting, finds a database analysis.

07-02-2019 | Prostate cancer | News

Adding docetaxel to ADT for high-risk nonmetastatic prostate cancer questioned

Supplementing androgen deprivation therapy with docetaxel does not appear to improve the outcomes of men with high-risk nonmetastatic prostate cancer and rising prostate-specific antigen levels after treatment, indicate phase III trial findings.

image credits